List of Excipients in Branded Drug VAZALORE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
PLx Pharma Inc	VAZALORE	aspirin	73089-081	ANHYDROUS CITRIC ACID	2032-09-29
PLx Pharma Inc	VAZALORE	aspirin	73089-081	CARRAGEENAN	2032-09-29
PLx Pharma Inc	VAZALORE	aspirin	73089-081	FD&C BLUE NO. 1	2032-09-29
PLx Pharma Inc	VAZALORE	aspirin	73089-081	HYPROMELLOSE	2032-09-29

VAZALORE Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 2, 2026

VAZALORE is a liquid-filled aspirin capsule built around PLx Pharma’s PLxGuard phospholipid delivery technology. Its commercial differentiation is the combination of aspirin with phospholipids intended to reduce direct gastric contact while preserving aspirin’s antiplatelet effect. The excipient system is therefore the product’s primary technical and intellectual-property differentiator, not a conventional inactive-ingredient choice.

The strongest commercial opportunities are premium low-dose aspirin, gastrointestinal-tolerability positioning, private-label expansion, international licensing, and follow-on products using the same phospholipid platform. The principal risks are aspirin’s low active-ingredient cost, limited reimbursement leverage, dependence on clinical differentiation, manufacturing complexity, and the need to distinguish formulation patents from regulatory exclusivity.

What is VAZALORE and how does its formulation differ from standard aspirin?

VAZALORE contains aspirin in a liquid-filled capsule with phospholipid excipients. The formulation is intended to reduce direct contact between aspirin and the gastric mucosa by incorporating the aspirin into a phospholipid-based delivery system.

Product characteristic	VAZALORE	Conventional enteric-coated aspirin	Immediate-release aspirin tablet
Active ingredient	Aspirin, also called acetylsalicylic acid	Aspirin	Aspirin
Dosage form	Liquid-filled capsule	Film- or polymer-coated tablet	Compressed tablet
Primary formulation strategy	Phospholipid delivery system	Delayed release	Rapid disintegration
Main commercial claim	Aspirin delivery with reduced gastric irritation potential	Delayed gastric release	Low cost and broad availability
Principal use	Cardiovascular risk reduction and analgesic indications, depending on strength and labeling	Cardiovascular risk reduction	Cardiovascular and analgesic indications
Manufacturing complexity	Higher	Moderate	Low
Brand differentiation	High relative to ordinary aspirin	Limited	Low

VAZALORE is marketed in 81 mg and 325 mg strengths. The 81 mg strength targets chronic antiplatelet use, where daily exposure and long-term gastrointestinal tolerability are central purchasing considerations. The 325 mg strength addresses higher-dose aspirin use, including analgesic and anti-inflammatory applications subject to product labeling.

The product’s differentiation depends on formulation behavior rather than on a new aspirin molecule. That distinction affects both pricing power and patent strategy. A competitor can use the same active ingredient while avoiding VAZALORE’s specific phospholipid composition, capsule architecture, manufacturing process, or therapeutic-use claims.

Which excipients are central to the VAZALORE formulation?

The commercially relevant excipient class is phospholipids. Public descriptions of the PLxGuard platform identify phospholipid-based delivery as the core technology, but the exact commercial formulation, quantitative composition, processing parameters, and supplier specifications are not fully disclosed in ordinary product marketing materials.

Potential excipient functions include:

Excipient function	Likely technical objective
Phospholipid carrier	Associate with aspirin and reduce direct gastric exposure
Lipid vehicle	Maintain a uniform liquid fill and support dispersion
Capsule shell	Contain the liquid formulation and control dose delivery
Antioxidant system	Limit oxidation of lipid components
Viscosity modifier	Maintain fill uniformity during encapsulation
Surfactant or co-solvent	Improve dispersion and physical stability
Moisture-control components	Protect aspirin and capsule integrity
Processing aid	Support reproducible softgel manufacture

The formulation must balance several competing requirements. Aspirin hydrolyzes to salicylic acid and acetic acid in the presence of moisture. A liquid-filled system therefore requires careful control of water activity, capsule-shell permeability, pH environment, temperature, oxygen exposure, and storage conditions.

The phospholipid system also creates physical-stability risks. Lipid oxidation, phase separation, sedimentation, viscosity drift, capsule leakage, and fill-weight variation can affect product quality. These risks make raw-material qualification and process control more important than in a standard aspirin tablet.

What excipient strategy creates the strongest commercial moat?

The strongest strategy is a multi-layer formulation platform rather than reliance on a single phospholipid ingredient.

Composition protection

A composition patent can cover the combination of aspirin with specified phospholipids, ratios, concentrations, or lipid classes. The commercial value depends on whether a competitor can obtain comparable performance using a different phospholipid or a materially different ratio.

Broad claims covering any aspirin-phospholipid combination are more valuable but face greater validity and enablement risk. Narrow claims covering specific lipid species or concentration ranges are easier to defend when supported by comparative data, but they may be easier to design around.

Dosage-form protection

Liquid-filled capsules create a separate protection layer. Claims may address:

• Aspirin dissolved or dispersed in a lipid vehicle
• Specific capsule compositions
• Fill-volume ranges
• Release behavior
• Moisture-control specifications
• Manufacturing sequence
• Encapsulation and sealing conditions

This protection is commercially relevant because a competitor may avoid a composition claim but still need to solve the same softgel stability and manufacturing problems.

Performance-based protection

The most defensible formulation estate would connect the excipient system to measurable product performance, such as reduced gastric injury, reduced aspirin crystallization, improved dissolution, or altered localization in the gastrointestinal tract.

Performance claims must be supported by appropriate analytical, pharmacokinetic, pharmacodynamic, or clinical evidence. A formulation that merely contains phospholipids has weaker commercial protection than a formulation linked to a demonstrated functional result.

Manufacturing protection

Manufacturing know-how may be more valuable than publicly visible patent claims. Relevant trade-secret areas include:

• Order of ingredient addition
• Temperature profile
• Shear rate and mixing time
• Deaeration
• Water-content limits
• Encapsulation speed
• Gelatin or non-gelatin shell processing
• In-process fill uniformity
• Packaging and oxygen-control specifications

Manufacturing barriers are particularly important because aspirin has a low per-dose cost. A generic competitor can tolerate modest formulation-development expense only if the product has enough price premium or market volume.

What patents protect VAZALORE and its PLxGuard technology?

VAZALORE’s patent position is expected to center on PLx Pharma’s PLxGuard platform and related aspirin-phospholipid formulations. The relevant patent categories are:

1. Aspirin-phospholipid compositions.
2. Oral dosage forms using phospholipid carriers.
3. Methods for reducing gastrointestinal injury associated with aspirin.
4. Methods of administering aspirin while maintaining antiplatelet activity.
5. Liquid-filled capsule formulations.
6. Manufacturing processes for phospholipid-containing dosage forms.

A precise freedom-to-operate opinion requires claim-by-claim review of issued U.S. patents, pending applications, terminal disclaimers, continuations, patent-term adjustments, and foreign counterparts. Product branding and technology descriptions do not establish the complete patent estate.

The commercial conclusion is clear: VAZALORE’s defensibility depends on claims that cover the functional formulation architecture, not merely the use of aspirin. Aspirin itself is long off patent and widely available. The enforceable value lies in the combination of aspirin, phospholipid delivery, dosage form, use, and manufacturing process.

What is the FDA regulatory status of VAZALORE?

VAZALORE is an FDA-regulated aspirin product marketed as a liquid-filled capsule. Its regulatory position is important because the product’s claims involve more than ordinary aspirin identity. The formulation and labeling must support the product’s dosage form, stability, quality attributes, and permitted therapeutic claims.

Key regulatory considerations include:

• FDA-approved labeling for the marketed strengths and indications.
• Chemistry, manufacturing, and controls requirements for the lipid-based formulation.
• Stability data covering aspirin degradation and lipid oxidation.
• Capsule integrity and dissolution testing.
• Bioavailability or pharmacodynamic data, where required.
• Labeling substantiation for gastrointestinal tolerability claims.
• Postmarketing monitoring for bleeding, hypersensitivity, and other aspirin-related risks.

VAZALORE’s regulatory status should be evaluated separately from its patent status. FDA approval does not establish freedom from patent infringement, and a patent does not guarantee regulatory exclusivity.

What is the Orange Book status of VAZALORE?

The Orange Book is the controlling source for determining whether an approved drug application has listed patents and whether those patents carry expiration dates relevant to generic approval. A product’s commercial website, packaging, or press release does not substitute for an Orange Book review.

For VAZALORE, the regulatory diligence should examine:

• The approved application number.
• Listed drug-substance patents, if any.
• Listed drug-product patents.
• Listed method-of-use patents.
• Patent-use codes.
• Delisting history.
• Generic certifications under Paragraph I, II, III, or IV.
• Any 30-month litigation stay.
• Exclusivity codes and expiration dates.

Because aspirin is an old active ingredient, any meaningful Orange Book protection would likely arise from the product formulation, dosage form, or approved method of use rather than from the aspirin molecule. The practical exposure depends on whether a generic applicant can certify that its product does not infringe listed patents or that the patents are invalid or unenforceable.

When does VAZALORE lose exclusivity?

VAZALORE’s exclusivity has several components:

Exclusivity layer	Relevance
Active-ingredient exclusivity	Minimal because aspirin is long established
Regulatory exclusivity	Depends on the application type and FDA-granted exclusivity
Formulation patents	May block substantially similar phospholipid products
Method-of-use patents	May limit labeled use, but often leave other uses open
Trade secrets	Can delay efficient replication without creating formal market exclusivity
Trademark protection	Protects the VAZALORE name, not the underlying formulation

The most important dates are the expiration dates of issued formulation and method patents, adjusted for patent-term adjustment, patent-term extension, terminal disclaimers, and post-grant proceedings. A patent expiration date should not be estimated from the filing date alone.

A generic could potentially launch before all patents expire if it uses a noninfringing formulation, omits protected indications, or succeeds in a Paragraph IV challenge. Conversely, a formulation patent may have limited practical effect if the generic product does not need to reproduce the protected phospholipid architecture.

What Paragraph IV challenges and generic-entry risks exist?

A Paragraph IV challenge could target one or more VAZALORE patents on the grounds that the claims are invalid, unenforceable, or not infringed. Likely technical arguments would include:

• Earlier disclosure of aspirin-lipid combinations.
• Obviousness based on known lipid drug-delivery systems.
• Lack of unexpected results across the full claim scope.
• Insufficient enablement for broad phospholipid classes.
• Design-around using a different lipid species or concentration.
• Noninfringement based on tablet, hard-capsule, or non-liquid dosage forms.
• Carve-out labeling for protected methods of use.

The main generic scenarios are:

Conventional aspirin substitution

A low-cost tablet or enteric-coated product competes on price but does not replicate VAZALORE’s formulation. This is the largest volume threat in the overall aspirin market.

Therapeutically substitutable premium product

A competitor markets a different low-irritation aspirin formulation. This could erode VAZALORE’s differentiation without infringing its patents.

Direct phospholipid formulation copy

A competitor uses a similar liquid-filled phospholipid system. This creates the highest litigation risk but also the clearest infringement case if claims are broad and valid.

Private-label licensing

Retailers or pharmacy chains could sell a licensed version under a store brand. This expands volume while potentially reducing VAZALORE brand pricing.

What commercial opportunities exist for VAZALORE excipients?

The excipient platform creates opportunities beyond the branded product.

Private-label and co-branded aspirin

The most direct opportunity is licensing the formulation to retailers, pharmacy chains, hospital systems, and cardiovascular-health brands. A platform license could include the phospholipid system, manufacturing specifications, quality controls, and trademark rights.

International licensing

Countries with high aspirin use, aging populations, and strong pharmacy distribution may support regional licensing. The commercial model could combine local softgel manufacture with centralized supply of a proprietary phospholipid premix.

Foreign patent coverage is critical. Protection may be weaker outside the United States because of differences in filing dates, national-phase prosecution, claim scope, compulsory licensing rules, and patent-term adjustments.

Combination products

Potential combinations include aspirin with statins, antihypertensive agents, or other cardiovascular medicines. These products could improve adherence but create substantial regulatory and formulation complexity. Chemical compatibility, dose flexibility, separate release requirements, and combination-product patenting would require new development work.

Other NSAID delivery systems

The platform could be evaluated with other acidic drugs where gastric exposure is commercially relevant. The opportunity is technically attractive but not automatic. Aspirin’s pharmacology, hydrolysis behavior, antiplatelet activity, and established clinical use make it distinct from ibuprofen, naproxen, and other NSAIDs.

Veterinary and institutional markets

Veterinary products and institutional cardiovascular protocols may offer lower customer-acquisition costs. These channels remain sensitive to price and procurement requirements, so the formulation premium must be supported by measurable tolerability or adherence benefits.

Excipient supply and CDMO services

A qualified supplier could sell:

• Pharmaceutical-grade phospholipid blends
• Standardized lipid premixes
• Antioxidant systems
• Softgel fill formulations
• Encapsulation services
• Stability-testing packages
• Process-development support

The highest-value position is an integrated platform with proprietary raw-material specifications and validated manufacturing parameters. Commodity phospholipid supply alone is less defensible.

How strong is the VAZALORE patent estate?

The estate is strongest where it combines composition, performance, and manufacturing claims. It is weaker where claims cover broad, predictable uses of known phospholipids without strong comparative evidence.

Patent asset	Expected strength
Aspirin molecule claims	Very low
Broad phospholipid use claims	Moderate to low, depending on prior art
Narrow composition claims	Moderate to high if commercially practiced
Liquid-filled capsule claims	Moderate
Manufacturing-process claims	High if difficult to detect and supported by trade secrets
GI-tolerability method claims	Variable and evidence-dependent
Trademark rights	Strong for brand identity, not product substitution

The estate should be valued through claim coverage of the actual marketed product, not by patent count. A small number of well-aligned formulation patents can provide more commercial value than a large portfolio of narrow applications that do not read on the product or are easy to design around.

What formulation and manufacturing barriers affect competitors?

The main barriers are formulation reproducibility and scale-up. A competitor must demonstrate:

• Consistent aspirin potency.
• Low degradation over shelf life.
• Uniform phospholipid dispersion.
• Acceptable capsule leakage rates.
• Appropriate dissolution.
• Stable fill viscosity.
• Robust packaging performance.
• Batch-to-batch raw-material consistency.

Softgel manufacturing also creates capital and operational constraints. Equipment qualification, gelatin-shell control, drying conditions, inspection, and defect rejection can increase cost. These factors favor companies with existing softgel capacity or an experienced contract manufacturer.

The barrier is lower for ordinary aspirin tablets. VAZALORE’s commercial moat therefore depends on retaining a meaningful price premium and communicating a clinically relevant benefit.

How does VAZALORE compare with other aspirin products?

VAZALORE competes against three categories:

1. Low-cost immediate-release aspirin, which dominates on price.
2. Enteric-coated aspirin, which offers delayed release but does not use the same phospholipid delivery concept.
3. Other branded low-gastrointestinal-impact products, if available in the relevant market.

VAZALORE has the strongest position among consumers who value formulation differentiation and are willing to pay for it. It has a weaker position in commodity institutional purchasing, where aspirin tablets are inexpensive and clinical protocols often prioritize standardized low cost.

Revenue exposure is concentrated in the 81 mg chronic-use segment. The 325 mg product broadens the addressable market but may face stronger substitution from generic analgesic and anti-inflammatory products.

Key Takeaways

• VAZALORE’s commercial identity is based on a phospholipid-containing liquid-filled aspirin capsule.
• The excipient system is the main source of product differentiation and potential patent value.
• Aspirin itself provides little meaningful exclusivity because it is a long-established active ingredient.
• The best patent strategy combines composition, dosage form, performance, and manufacturing claims.
• Generic risk is highest from design-around products that use different lipid systems or dosage forms.
• Private-label licensing, international partnerships, phospholipid premixes, and CDMO services are the clearest commercial opportunities.
• The 81 mg strength is the primary chronic-use commercial asset.
• Manufacturing controls, lipid stability, moisture management, and capsule integrity are material barriers to replication.
• Orange Book listings, approved application data, patent-use codes, and Paragraph IV history must be reviewed to establish the operative U.S. exclusivity position.
• Patent value should be measured by claim coverage of the marketed formulation, not by the number of patents in the portfolio.

FAQs

Can a generic company copy VAZALORE using ordinary aspirin tablets?

Yes. A conventional aspirin tablet can compete therapeutically in many markets without reproducing the phospholipid liquid-filled formulation. It would not necessarily infringe formulation claims, but it could erode market share through price substitution.

Are phospholipids in VAZALORE pharmaceutical excipients or active ingredients?

They are used as formulation excipients and delivery components. Their regulatory significance depends on composition, concentration, functional role, and the product’s approved chemistry, manufacturing, and controls data.

Does an enteric-coated aspirin product infringe VAZALORE patents?

Not necessarily. Enteric coating and phospholipid delivery are different formulation approaches. Infringement depends on the specific patent claims and the technical composition of the competing product.

Could VAZALORE technology be used for ibuprofen?

Potentially, but transferability is not established by the aspirin product alone. Ibuprofen would require separate compatibility, stability, dissolution, clinical, and regulatory development.

What is the most valuable licensing asset associated with VAZALORE?

The most valuable asset is likely the integrated PLxGuard formulation and manufacturing package, including excipient specifications, process parameters, quality controls, regulatory support, and any enforceable patent rights.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Aspirin and nonsteroidal anti-inflammatory drug labeling. https://www.fda.gov/

4. PLx Pharma Inc. (n.d.). VAZALORE aspirin capsules and PLxGuard delivery technology. Company product materials.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

6. World Intellectual Property Organization. (n.d.). PATENTSCOPE patent search database. https://patentscope.wipo.int/